Table 3

Genetic contrasts	Population	Heterogeneity	Model used	OR (95% CI) p_OR	Egger's test；
Genetic contrasts	Population	ph; I2	Model used	OR (95% CI) p_OR	t; p_E; (95% CI)
AA vs. AG+GG	Overall	0.019; 56.3%	random-effects (D-L)	1.11 (0.91-1.35) 0.305	0.54; 0.609 (-2.59-4.11)
AA vs. AG+GG	Caucasion	0.012; 61.1%	random-effects (D-L)	1.10 (0.88-1.37) 0.402	0.54; 0.609 (-2.59-4.11)
AA+AG vs. GG	Overall	0.531; 0.0%	fixed-effects (M-H)	1.13 (0.83-1.54) 0.449	0.77; 0.464 (-5.08-1.00)
AA+AG vs. GG	Caucasion	0.425; 0.6%	fixed-effects (M-H)	1.13 (0.82-1.55) 0.445	0.77; 0.464 (-5.08-1.00)
A vs. G	Overall	0.016; 57.5%	random-effects (D-L)	1.09 (0.92-1.30) 0.321	0.57; 0.587 (-2.84-4.64)
A vs. G	Caucasion	0.010; 62.3%	random-effects (D-L)	1.08 (0.89-1.31) 0.414	0.57; 0.587 (-2.84-4.64)

Note: D-L, the DerSimonian-Laird method; M-H, the Mantel-Haenszel method; p_h, p-value of Q-test for heterogeneity test; p_OR, p-value of Z-test for OR; p_E, p-value of t-test for Egger’s test.

Table 3: Main results of heterogeneity pooled ORs, stratification analysis and Egger’s test of the MTR gene functional polymorphisms on AD risk in the meta analysis.